Christopher Ray Aker Sells 38,547 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) VP Christopher Ray Aker sold 38,547 shares of the firm’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $48,569.22. Following the completion of the sale, the vice president now directly owns 54,634 shares in the company, valued at approximately $68,838.84. This represents a 41.37 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Regulus Therapeutics Stock Up 3.7 %

Shares of RGLS stock traded up $0.05 during mid-day trading on Wednesday, reaching $1.27. 283,082 shares of the stock traded hands, compared to its average volume of 348,120. The company has a market cap of $83.19 million, a price-to-earnings ratio of -1.19 and a beta of 1.60. The stock’s fifty day simple moving average is $1.53 and its two-hundred day simple moving average is $1.59. Regulus Therapeutics Inc. has a 1-year low of $1.08 and a 1-year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, equities research analysts anticipate that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Regulus Therapeutics

A number of hedge funds have recently modified their holdings of RGLS. Creative Planning bought a new position in Regulus Therapeutics during the 3rd quarter worth $26,000. SG Americas Securities LLC acquired a new stake in shares of Regulus Therapeutics in the third quarter valued at about $33,000. Jane Street Group LLC bought a new position in shares of Regulus Therapeutics during the third quarter worth about $46,000. State Street Corp lifted its stake in shares of Regulus Therapeutics by 3.5% in the third quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock worth $1,572,000 after acquiring an additional 33,496 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in shares of Regulus Therapeutics by 10.4% in the third quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock worth $626,000 after acquiring an additional 37,480 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Wall Street Analysts Forecast Growth

RGLS has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research report on Monday, November 11th. StockNews.com raised shares of Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.